Jury Awards $8 Million in Damages for Metal Hip Replacement

March 20, 2013

A Los Angeles jury has ordered the healthcare giant Johnson & Johnson, the world’s biggest medical products maker, to pay $8 million in damages for injuries resulting from the all metal hip replacement made by DePuy, the orthopedic branch of Johnson & Johnson.

This is the first verdict and award in nearly 11,000 suits filed against the company for the DePuy metal hip replacements.

Loren Kransky, a retired prison guard, claimed the all metal ball and socket hip implant left him with crippling injuries, and the jury agreed.  The jury found the implant was defectively designed, which lead to metal poisoning and other health issues suffered by Kransky.

Johnson & Johnson pulled the product from the market about 2 years ago, but has set aside around $3 billion to cover the costs of recalling defective hip implants and law suits resulting from these implants.

This verdict sends a clear message that the claims arising from the DePuy hip implant are real and cause severe and significant damages which Johnson & Johnson will be held accountable for.

During the trial, Kransky’s lawyers demonstrated how the all metal hip implant would deteriorate and some of the metal would flake off, causing metal poisoning which led to Kransky’s health issues and could potentially have killed him.  Despite the defense bringing up Kransky’s long history of past health problems, the jury returned a verdict ordering Johnson & Johnson to pay.

The artificial hip implant was made to help with pain and mobility issues.  The hip joint was sold for more than 8 years to more than 90,000 people worldwide.  In 2008, roughly 40% of U.S. hip replacements were all metal.  By 2009 pulled from the market and Johnson & Johnson stopped manufacturing them.

If you received a metal hip implant and believe it is causing health issues, please contact The Brad Hendricks Law Firm, located in Little Rock, Arkansas, at (501) 588-0549 or toll free (866) 676-5096 today.


Injured by Yaz?

March 12, 2013

Yaz, Yasmin, Ocella Birth Control Injuries Litigation

The Brad Hendricks Law Firm wants to help if you or a loved one has been harmed by Yaz (also known as Yasmin and by its generic name "Ocella").

Originally developed and manufactured by Berlex Laboratories, these medications are referred to as "combination birth control," which contain the hormones estrogen (ethinyl estradiol) and progestin (drospirenone or "drsp"). Yasmin was approved by the Food and Drug Administration on May 11, 2001.

Bayer AG acquired Berlex Laboratories in 2006 and began marketing this product as "a "different type of birth control pill." At one point, Yaz was marketed as an effective treatment of premenstrual syndrome (PMS), but in October 2008, the FDA issued a warning letter for this deceptive claim and clarifying that the medication was only meant to help treat Premenstrual Dysphoric Disorder (PMDD) while simultaneously reducing the effects of acne. This marketing campaign was highly effective and today it is the number one birth control pill in the United States, with more than $600 million sales in 2008.

Unfortunately, this "different type of birth control pill" that was marketed as offering such additional perks, in addition to preventing pregnancy, is not without its risks. Some women might simply experience symptoms such as:

Severe Headaches

Severe allergic reactions including rash, hives, itching, difficulty breathing.

Tightness in the chest swelling of the mouth, face, lips, or tongue.


Irregular heartbeat

Symptoms of liver problems

Unusual or severe vaginal bleeding

Unusual tiredness or weakness

Vaginal irritation or discharge

Vision changes (eg, sudden vision loss, double vision)

For others, however, the risks are much higher and include the following:

Heart Attack

Cardiac Arrhythmias


Pulmonary embolism (an artery in the lung is blocked)

Blood Clots (Non-Vaginal)

Kidney Complications and Kidney Failure


Deep Vein Thrombosis (DVT)

Gallbladder Disease

Hepatic Adenomas


Sudden Death

There have been more than 50 reports of deaths filed with the FDA since 2004.

The Brad Hendricks Law Firm believes that these risks are simply unacceptable. If you or someone you love have experienced any of these symptoms after taking Yaz, Yasmin, or Ocella, you may be entitled to compensation. For a free consultation with an experienced attorney about your claim, please contact us today at (501) 588-0549 or (866) 676-5096 today!

Injured by GranuFlo® and NaturaLyte® Dry Acid Concentrate while on Dialysis?

March 12, 2013

Call The Brad Hendricks Law Firm Today!

The Brad Hendricks Law Firm, a full-service law firm located in Little Rock, Arkansas, is investigating claims of severe complications associated with the of GranuFlo® and NaturaLyte® Dry Acid Concentrate during dialysis treatments.  The use of these products has been linked to a significant increase in the risk of cardiopulmonary events, including cardiac arrest and even death.

On March 29, 2012, the United States Food and Drug Administration announced that it was recalling Naturalyte Liquid and Granuflow Dry Acid Concentrate, both of which are manufactured by Fresenius Medical Care North America.  The recall was identified as a Class I recall, "the most serious type of recall," which are appropriate when the FDA determines"there is a reasonable probability that use of a product will cause "serious adverse health consequences or death."

The concentrate, formulated for use with a three-stream hemodialysis machine, has been recommended for the treatment of acute and chronic renal (kidney) failure in patients undergoing dialysis treatments.  According to the FDA, the concentration of acetate or sodium diacetate contained in Fresenius’ Naturalyte Liquid and GranuFlo Dry Acid Concentrate, when improperly administered, can lead to a high serum bicarbonate level in dialysis patients which may contribute to "metabolic alkadosis."

Metabolic alkadosis, the FDA warns, is a significant risk factor associated with the following: 

Heart Problems, including Myocardial Infarction or Heart Attack

Low Blood Pressure

Hypokalemia, Hypoxemia, Hypercapnia

Cardiac Arrythmia


If not properly treated, cardiopulmonary arrest or even death may result.  In fact, cardiac death has been identified as the leading cause of death of dialysis patients!

Reports suggest that FMC officials knew that high pre-dialysis serum bicarbonate levels increased patients’ risk of cardiac arrest and death at all times, but they continued to market Naturalyte and GranuFlo, anyway.  What’s worse, FMC continues to market the products, placing hundreds of thousants of patients undergoing dialysis at any of the thousands of dialysis clinics across the country, at risk!

Call The Brad Hendricks Law Firm if you believe you have been injured by Naturalyte Liquid and GranuFlo Dry Acid Concentrate

If You or a Loved One has suffered any of the side effects listed above, including cardiac arrest, while undergoing dialysis, and you believe that Naturalyte or GranuFlo may have contributed to your injuires, please call The Brad Hendricks Law Firm today at (501) 588-0549 or (866) 676-5096 for a free consultation with an experienced team of lawyers and professionals.  You can count on us to make sure you are compensated for your injuries!

Injured by Transvaginal Mesh/Bladder Slings to treat Pelvic Organ Prolapse or Stress Urinary Incontinence?

July 30, 2012
Little Rock, AR Transvaginal Mesh and Bladder Sling Attorneys

Transvaginal Mesh and Pelvic Organ Prolapse & Stress Urinary IncontinenceThe Brad Hendricks Law Firm is investigating claims of severe complications associated with the use of transvaginal surgical mesh and bladder slings, which have been surgically installed to treat Pelvic Organ Prolapse (“POP”) and Stress Urinary Incontinence (“SUI”).

Pelvic Organ Prolapse occur when pelvic organs drop from their normal position because the tissues and muscles of the pelvic floor are no longer able to support the organs, which the uterus and bladder.  The muscles and tissue may become torn or weakened because of childbirth or age.  For several years surgical mesh has been used to treat POP and stress urinary incontinence.

Historically, surgical mesh has been used since the 1950s to repair abdominal hernias.  In the 1970s, gynecologists incorporated surgical mesh to treat POP.  Surgical mesh has been used to treat transvaginal POP and SUI since the 1990s.

In 2008, the United States Food and Drug Administration (“FDA”) issued a Public Health Notification (“PHN”) to warn patients about adverse effects related to urogynecologic use of surgical mesh.  Between January 1, 2008, and December 31, 2010, 2,874 medical device reports (“MDR”) were submitted chronicling complaints of malfunction, injury and even death.  Of those reports, 1,503 were associated with POP, while 1,371 reports were associated with SUI repairs.  There were 3,979 reports of injury, death and malfunction between January 1, 2005, and December 31, 2010.

Unfortunately, the FDA has reported, “[m]esh-associated complications are not rare.”  Approximately 10 of women undergoing transvaginal POP repair experience vaginal mesh erosion within 12 months of surgery.  Mesh contraction, which can cause vaginal shortening, tightening, or vaginal pain is increasingly reported by patients.  Some patients require numerous follow up procedures.

Common Complications from Surgeries that Insert Transvaginal Mesh and Bladder Slings

The most common complications associate with the use of transvaginal mesh and bladder slings include the following:

Mesh erosion through the vaginal tissue
Chronic vaginal drainage
Erosion of the vaginal tissue
Feeling as though something is protruding from the vagina
Lower back pain
Pain during intercourse and Vaginal Pain not related to intercourse
Perforations of the bowel, bladder or blood vessels
Pressure or feeling of “fullness” in the lower abdomen
Reoccurrence of pelvic organ prolapse (POP) or stress urinary incontinence (SUI)
Continued urinary problems
Vaginal bleeding
Vaginal infections
Vaginal pain not related to intercourse
Vaginal scarring

The Securities and Exchange Commission has reported that approximately 47,000 women have received pelvic mesh implants.  To date, more than 600 lawsuits have been filed against manufacturers.

Call Us if You or a Loved One has Been Injured by Transvaginal Mesh used to treat POP or SUI

The Brad Hendricks Law Firm wants to know if you or a loved one has been harmed by transvaginal mesh/bladder slings used to treat Pelvic Organ Prolapse and Stress Urinary Incontinence.  Call The Brad Hendricks Law Firm today at (501) 588-0549 or (866) 676-5096 for a free consultation with an experienced team of lawyers and professionals. If you or a loved one has been harmed by this urological or gynecological use of surgical mesh, you can count us to fight to make sure you are compensated for your injuries.

Enhanced by Zemanta

Have You or a Loved One Taken Topamax?

April 27, 2011

image On March 4, 2011, the Food and Drug Administration issued a news release notifying the public of an increased risk of oral birth defects in children born to mothers who have taken the anticonvulsant drug Topamax (Topiramate) while pregnant. 

Cleft lip and cleft palate, collectively called oral clefts, are birth defects that occur when parts of the lip or palate do not completely fuse together early in the first trimester of pregnancy, a time when many women do not know they are pregnant. The defects range from a small notch in the lip to a groove that runs into the roof of the mouth and nose, possibly leading to problems with eating, talking, and to ear infections. Surgery often is performed to close the lip and palate and most children do well after treatment.

Other congenital birth defects may also occur, including limb malformations, heart defects, persistent pulmonary hypertension of the newborn, lung defects, hypospadias, craniofacial defects and neural tube defects. 

Topamax (Topiramate) is generally prescribed to treat epilepsy in children and adults, as well as Lennox-Gastault syndrome (which also causes seizures and developmental delays).  Topamax and its generic versions are also used to prevent migraine headaches

According to Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, “Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age. . . .  Alternative medications that have a lower risk of birth defects should be considered.”  Patients should not stop taking topiramate unless directed to do so by their health care professional, however, it is vital for women who are, or who may become pregnant while taking topiramate, to discuss other treatment options with their health care professional. 

Topamax had previously been marketed for the treatment of bipolar disorder, weight loss, alcohol dependence, post-traumatic stress disorder, depression, autism, and other conditions.  In May 2010, the manufacturers of Topamax pled guilty to illegally promoting Topamax for these and other unapproved psychiatric uses, even though the FDA had not granted approval of the drug for such uses.  As part of a settlement, the manufacturers were forced to pay fines exceeding $81 million.

Women who become pregnant while taking topiramate should talk to their health care professional about registering with the North American Antiepileptic Drug Pregnancy Registry, a group that collects information about outcomes in infants born to women treated with antiepileptic drugs during pregnancy. 

If you or a loved one took Topamax or its generic variant (Topiramate) and have given birth to a child with a cleft lip, cleft palate, or other birth defects, please call The Brad Hendricks Law Firm today at (501) 221-0444 or (501) 588-0549 or (866) 676-5096.